AU6906100A - Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis - Google Patents
Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosisInfo
- Publication number
- AU6906100A AU6906100A AU69061/00A AU6906100A AU6906100A AU 6906100 A AU6906100 A AU 6906100A AU 69061/00 A AU69061/00 A AU 69061/00A AU 6906100 A AU6906100 A AU 6906100A AU 6906100 A AU6906100 A AU 6906100A
- Authority
- AU
- Australia
- Prior art keywords
- receptor
- fusion protein
- mediated uptake
- protein inhibits
- inhibits apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14922099P | 1999-08-16 | 1999-08-16 | |
US60/149220 | 1999-08-16 | ||
PCT/US2000/022293 WO2001012661A2 (en) | 1999-08-16 | 2000-08-15 | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6906100A true AU6906100A (en) | 2001-03-13 |
Family
ID=22529285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU69061/00A Abandoned AU6906100A (en) | 1999-08-16 | 2000-08-15 | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6906100A (en) |
WO (1) | WO2001012661A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2496400A1 (en) * | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
BRPI0613387A2 (en) * | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | isolated antibody or antigen binding fragment thereof and its use, isolated polynucleotide, composition, vector, host cell, anti-sp35 antibody and method for producing the same, isolated polypeptide, in vitro method for reducing inhibition of axonal growth and in vitro method for inhibiting cone collapse growth |
US20100317577A1 (en) * | 2005-09-09 | 2010-12-16 | Department Of Health And Human Services | Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation |
WO2007123791A2 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
FR2988393B1 (en) * | 2012-03-20 | 2014-05-09 | Commissariat Energie Atomique | INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT |
AU2013317985B2 (en) | 2012-09-19 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
JP6663852B2 (en) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | BH3 profiling method |
KR20180018507A (en) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | Prediction of Response to Albosis Dip by Mitochondrial Profiling |
US20180120297A1 (en) | 2015-04-27 | 2018-05-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
MX2017014645A (en) | 2015-05-18 | 2018-01-23 | Tolero Pharmaceuticals Inc | Alvocidib prodrugs having increased bioavailability. |
WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
CN110234659A (en) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | Analytical peptide and method for sensitivity analysis |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
JP2022525149A (en) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677274A (en) * | 1993-02-12 | 1997-10-14 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Anthrax toxin fusion proteins and related methods |
WO1997041227A1 (en) * | 1996-05-01 | 1997-11-06 | T Cell Sciences, Inc. | Plasmid-based vaccine for treating atherosclerosis |
US5856445A (en) * | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
-
2000
- 2000-08-15 WO PCT/US2000/022293 patent/WO2001012661A2/en active Application Filing
- 2000-08-15 AU AU69061/00A patent/AU6906100A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001012661A2 (en) | 2001-02-22 |
WO2001012661A3 (en) | 2001-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5151100A (en) | Extracellular signaling molecules | |
AU1434899A (en) | Skin-compatible hand cleansers, particularly coarse hand cleansers | |
AU2610599A (en) | N-terminally truncated glp-1 derivatives | |
AU4488200A (en) | Modified protein matrices | |
AU6906100A (en) | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis | |
AU4409099A (en) | Human transmembrane proteins | |
AU3562299A (en) | Inhibin-hbc fusion protein | |
AU2557600A (en) | Skin lightening agents | |
AU2001241100A1 (en) | Polypeptide inducing apoptosis | |
AU4184299A (en) | Human apoptosis associated proteins | |
AU2373800A (en) | Neuron-associated proteins | |
AU5235699A (en) | Sulfonamide derivatives | |
AU2575000A (en) | Collagen-binding physiologically active polypeptide | |
AU1825300A (en) | Chimeric biotin-binding papillomavirus protein | |
AU3916400A (en) | Human transmembrane proteins | |
AU4972100A (en) | Current limiting composite material | |
AU1406001A (en) | Auto-adhesive composition | |
AU5446499A (en) | Apoptosis inducing agents | |
AU5619100A (en) | Intracellular signaling molecules | |
AU5394300A (en) | Tissue engineering | |
AU1705300A (en) | Novel ultrasound contrast agents | |
AU5552700A (en) | Chimeric proteins mediating targeted apoptosis | |
AU4352000A (en) | Clasp-2 transmembrane proteins | |
AU7353500A (en) | Apoptosis proteins | |
AU5233699A (en) | Sulfonamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |